The switch from interferon-β to natalizumab treatment is more effective in patients with relapsing forms of multiple sclerosis when administered early during the disease course

被引：0
|
作者：
Lourbopoulos, A. [1 ]
Giantzi, V. [1 ]
Chatzikyriakou, E. [1 ]
Liaptsi, E. [1 ]
Tascos, N. [1 ]
Grigoriadis, N. [1 ]
机构：
[1] AHEPA Univ Hosp, Thessaloniki, Greece
来源：
MULTIPLE SCLEROSIS JOURNAL | 2012年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：217 / 218
页数：2
相关论文
共 50 条
  • [1] Occurrence of thyroid autoimmunity in relapsing remitting multiple sclerosis patients undergoing interferon-β treatment
    Martinelli, V
    Gironi, M
    Rodegher, M
    Martino, G
    Comi, G
    ITALIAN JOURNAL OF NEUROLOGICAL SCIENCES, 1998, 19 (02): : 65 - 67
  • [2] Occurrence of thyroid autoimmunity in relapsing remitting multiple sclerosis patients undergoing interferon-β treatment
    V. Martinelli
    M. Gironi
    M. Rodegher
    G. Martino
    G. Comi
    The Italian Journal of Neurological Sciences, 1998, 19 : 65 - 67
  • [3] Enhanced Axonal Metabolism during Early Natalizumab Treatment in Relapsing-Remitting Multiple Sclerosis
    Wiebenga, O. T.
    Klauser, A. M.
    Schoonheim, M. M.
    Nagtegaal, G. J. A.
    Steenwijk, M. D.
    van Rossum, J. A.
    Polman, C. H.
    Barkhof, F.
    Pouwels, P. J. W.
    Geurts, J. J. G.
    AMERICAN JOURNAL OF NEURORADIOLOGY, 2015, 36 (06) : 1116 - 1123
  • [4] Vitamin D and disease activity in multiple sclerosis before and during interferon-β treatment
    Loken-Amsrud, Kristin I.
    Holmoy, Trygve
    Bakke, Soren J.
    Beiske, Antonie Giaever
    Bjerve, Kristian S.
    Bjornara, Bard T.
    Hovdal, Harald
    Lilleas, Finn
    Midgard, Rune
    Pedersen, Tom
    Benth, Jurate Saltyte
    Sandvik, Leiv
    Torkildsen, Oivind
    Wergeland, Stig
    Myhr, Kjell-Morten
    NEUROLOGY, 2012, 79 (03) : 267 - 273
  • [5] Rebound Disease Activity Reduction in Relapsing Multiple Sclerosis Patients Transitioned From Natalizumab to Teriflunomide
    Cohan, Stanley
    Edwards, Keith R.
    Chen, Chiayi
    Gervasi, Tiffany
    O'Connor, Judy
    Smoot, Kyle
    Kresa-Reahl, Kiren
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 70 - 70
  • [6] Rebound disease activity reduction in relapsing multiple sclerosis patients transitioned from natalizumab to teriflunomide
    Cohan, S.
    Edwards, K.
    Chen, C.
    Gervasi, T.
    O'Connor, J.
    Smoot, K.
    Kresa-Reahl, K.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 313 - 313
  • [7] Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis
    O'Connor, P. W.
    Goodman, A.
    Kappos, L.
    Lublin, F. D.
    Miller, D. H.
    Polman, C.
    Rudick, R. A.
    Aschenbach, W.
    Lucas, N.
    NEUROLOGY, 2011, 76 (22) : 1858 - 1865
  • [8] Natalizumab is effective in relapsing-remitting multiple sclerosis patients with advanced disease severity over 3 years
    Kallweit, U.
    Jelcic, I.
    Braun, N.
    Fischer, H.
    Zoerner, B.
    Schreiner, B.
    Sokolov, A.
    Linnebank, M.
    ALLERGOLOGIE, 2011, 34 (02) : 115 - 115
  • [9] Neurotrophic factors in relapsing-remitting and secondary progressive multiple sclerosis patients during interferon-β therapy
    Caggiula, M
    Batocchi, AR
    Frisullo, G
    Angelucci, E
    Patanella, AK
    Sancricca, C
    Nociti, V
    Tonali, R
    Mirabello, M
    MULTIPLE SCLEROSIS, 2004, 10 (7032): : S236 - S236
  • [10] Effect of natalizumab on relapses in patients with relapsing multiple sclerosis who experience MRI activity during treatment
    Bates, David
    Bartholome, Emmanuel
    Pace, Amy
    Hyde, Robert
    Hotermans, Christophe
    MULTIPLE SCLEROSIS, 2008, 14 : S31 - S31
12345